John Raymond Murphy
John Raymond Murphy's purchase track record
John Raymond Murphy has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/4/2023 | CVKD | $14K | -10.4% | -15.8% | +22.2% |
| 3/16/2023 | CVKD | $47K | +1.9% | -47.8% | +13.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cadrenal hires Tungsten Advisors to drive strategic process. Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.
Transaction History
| ORLY | ▼ Sell | Open Market | 2,595 | $230K | 5/18/2026 | View on chart |
| ORLY | ▲ Buy | Grant | 2,035 | $180K | 5/15/2026 | View on chart |
| ORLY | ▼ Sell | Open Market | 3,125 | $289K | 11/4/2025 | View on chart |
| ORLY | ▼ Sell | Open Market | 200 | $276K | 5/19/2025 | View on chart |
| ORLY | ▲ Buy | Grant | 131 | $181K | 5/16/2025 | View on chart |
| ORLY | ▲ Buy | Grant | 173 | $175K | 5/17/2024 | View on chart |
| ORLY | ▼ Sell | Open Market | 269 | $280K | 2/13/2024 | View on chart |
| ORLY | ▼ Sell | Open Market | 250 | $232K | 10/31/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 2,669 | $2K | 10/5/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 17,331 | $12K | 10/4/2023 | View on chart |
| ORLY | ▲ Buy | Grant | 169 | $161K | 5/19/2023 | View on chart |
| ORLY | ▼ Sell | Open Market | 300 | $277K | 5/2/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 10,000 | $14K | 3/21/2023 | View on chart |
| CVKD | ▲ Buy | Open Market | 20,000 | $33K | 3/16/2023 | View on chart |
| ORLY | ▼ Sell | Open Market | 300 | $255K | 2/14/2023 | View on chart |
| CVKD | ▼ Sell | Other | 514,792 | — | 1/24/2023 | View on chart |
| ORLY | ▼ Sell | Open Market | 300 | $212K | 8/2/2022 | View on chart |
| ORLY | ▲ Buy | Grant | 248 | $158K | 5/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ORLY Faces Earnings Watch Amid Mixed Analyst Views
Investors are watching O'Reilly Automotive ahead of its next earnings report, with questions about whether it will beat estimates again. While some analysts view the stock as a high-quality compounder at a reasonable valuation, others suggest it may be overlooked. The company is currently trading within its 52-week range, with an average analyst target of $107.35.
ORLY Faces Earnings Watch Amid Mixed Analyst Views. Investors are watching O'Reilly Automotive ahead of its next earnings report, with questions about whether it will beat estimates again. While some analysts view the stock as a high-quality compounder at a reasonable valuation, others suggest it may be overlooked. The company is currently trading within its 52-week range, with an average analyst target of $107.35.